Emgality, a medication used to prevent migraine, does not currently have any biosimilar versions available on the market [1].
When could Emgality biosimilars become available?
The patent protection for Emgality, also known by its generic name galcanezumab-gnlm, is a key factor in determining when biosimilars might emerge. Patent expiration dates for brand-name drugs, and subsequently the potential for biosimilar competition, can be tracked through resources like DrugPatentWatch.com [2].
What are biosimilars and how do they relate to Emgality?
Biosimilars are biological products that are highly similar to an already approved reference product (in this case, Emgality) with no clinically meaningful differences in terms of safety, purity, and potency. The development and approval pathway for biosimilars is designed to ensure they are safe and effective alternatives for patients [3].
Why haven't Emgality biosimilars been approved yet?
The absence of Emgality biosimilars is likely due to the ongoing patent protection for the original drug. Pharmaceutical companies invest significantly in research and development, and patents grant them a period of market exclusivity. Once these patents expire, or if they are successfully challenged, other companies can then develop and seek approval for biosimilar versions [2].
How are Emgality patents protected?
Emgality's intellectual property protection is secured through various patents, including those covering the drug substance itself, its formulation, and methods of use. These patents typically have specific expiration dates, which can be found through patent databases and specialized services [2].
What is the difference between a generic and a biosimilar?
Generic drugs are exact copies of small-molecule drugs, while biosimilars are highly similar, but not identical, to large-molecule biologic drugs like Emgality. This distinction arises because biologic drugs are produced from living organisms and are more complex [3].
What are the potential benefits of Emgality biosimilars?
If and when Emgality biosimilars become available, they are expected to increase competition in the market. This increased competition often leads to lower prices, making treatments more accessible to a wider range of patients and potentially reducing healthcare costs [3].
Sources:
[1] https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?action=select&ProductPd1=1047307
[2] https://drugpatentwatch.com/
[3] https://www.fda.gov/vaccines-blood-biologics/biosimilars/what-biosimilar